Clarius Mobile Health of Vancouver, B.C., has won FDA approval to market an AI model that works with the company’s handheld point-of-care ultrasound devices to identify and measure tendons of the foot, ankle and knee.

The model augmented and significantly improved diagnostic performance for abdominal subspecialists as well as residents—a result researchers say has major clinical implications.

Radiomics features could be especially useful for determining TSS in scenarios where clinical data is lacking or unreliable, such as when patients have altered mental status.

“To drive adoption, it is important that the technology designed to help productivity doesn’t add more work and complexity,” Dr. Mathias Goyen, Chief Medical Officer for Europe, the Middle East and Africa (EMEA) at GE HealthCare, told Health Imaging.

The move comes as Walgreens is shoring up its business amid a period of big transactions in the healthcare space.

The device, designed to be worn for up to 24 hours at a time, uses ultrasound technology and artificial intelligence to track how much blood the user's heart is pumping.

A team of specialists out of Cedars-Sinai developed the deep learning model using TTEs from nearly 3,000 patients.

Overwhelmed or confused by AI and machine learning technology? A new analysis in European Heart Journal hopes to provide some clarity.